HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shobe, J. Articles by Ruf, W. Search for Related Content PubMed PubMed Citation Articles by Shobe, J. Articles by Ruf, W. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 34, 24171-24175, August 20, 1999

Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex Is Independent of Scissile Bond Docking^*

Justin Shobe, Craig D. Dickinson, Thomas S. Edgington, and Wolfram Ruf

From the Departments of Immunology and Vascular Biology, The Scripps Research Institute, La Jolla, California 92037

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The upstream coagulation enzymes are homologous trypsin-like serine proteases that typically function in enzyme-cofactor complexes, exemplified by coagulation factor VIIa (VIIa), which is allosterically activated upon binding to its cell surface receptor tissue factor (TF). TF cooperates with VIIa to create a bimolecular recognition surface that serves as an exosite for factor X binding. This study analyzes to what extent scissile bond docking to the catalytic cleft contributes to macromolecular substrate affinity. Mutation of the P1 Arg residue in factor X to Gln prevented activation by the TF·VIIa complex but did not reduce macromolecular substrate affinity for TF·VIIa. Similarly, mutations of the S and S' subsites in the catalytic cleft of the enzyme VIIa failed to reduce affinity for factor X, although the affinity for small chromogenic substrates and the efficiency of factor X scissile bond cleavage were reduced. Thus, docking of the activation peptide bond to the catalytic cleft of this enzyme-cofactor complex does not significantly contribute to affinity for macromolecular substrate. Rather, it appears that the creation of an extended macromolecular substrate recognition surface involving enzyme and cofactor is utilized to generate substrate specificity between the highly homologous, regulatory proteases of the coagulation cascade.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

In higher organisms, serine proteases serve highly specialized functions in host defense, wound repair, and differentiation. The chymotrypsin-like subclass of the serine protease family is characterized by a conserved fold of the ~240-residue protease domain, resulting in an optimal positioning of the catalytic triad Ser-195 and His-57 residues in an invariable position (residue positions are based on chymotrypsin numbering; for corresponding VIIa¹ numbering, see Ref. 1). The most important determinant for serine protease specificity is the S1 specificity pocket that accommodates the P1 residue (residue 15 in chymotrypsin numbering) located amino-terminal to the scissile bond (2). The charge and shape properties of this pocket determine the fit of the P1 side chain and the proper presentation of the peptide bond for nucleophilic attack by Ser-195. Certain subsets of this protease family are evolutionary closely related and constitute functionally cooperating enzyme systems, such as the coagulation cascade (3). In the latter, the proteases share an acidic Asp-189 residue that forms the bottom of the S1 specificity pocket and thus are capable of cleaving very similar substrates that contain an Arg at the P1 position. Despite this identical P1 residue in all zymogen precursors of these enzymes, the coagulation proteases show remarkable macromolecular substrate specificity, allowing for a highly regulated consecutive activation of the individual zymogens in the cascade.

Substrate specificity determinants of these enzymes thus likely involve structural characteristics other than the S1 pocket. A large number of studies, employing either small peptidyl substrate mimics or inhibitors that bind to the active site, have provided evidence that the catalytic clefts of the coagulation proteases have distinct features that prefer certain residues in more extended positions on both sites of the scissile bond (4-8). Protein engineering has further been employed to demonstrate that determinants in the active site cleft are critical for substrate specificity of coagulation proteases (9-11). However, modifications of small peptide substrates at the P2-P3 or at P' subsite positions typically generate substrate selectivity that differs by less than 10-fold between coagulation enzymes (5, 8, 12). Considering the similarity in sequence at the scissile bond of the coagulation serine protease zymogens, the observed changes in catalytic efficiency for small substrates cannot entirely explain the high degree of selectivity for macromolecular substrate.

Macromolecular substrate activation by coagulation proteases depends on protein cofactor/receptors that localize these enzymes to cell surfaces. In the initiation phase of coagulation, tissue factor (TF), a transmembrane receptor structurally related to the cytokine receptor family, forms a high affinity complex with coagulation factor VIIa (VIIa) (13). One result of TF·VIIa complex formation is allosteric activation of VIIa. VIIa makes an incomplete zymogen to enzyme transition after proteolytic cleavage, and TF binding to the VIIa protease domain likely activates catalytic function by ordering loop segments of the activation domain (14). TF not only influences the catalytic cleft of VIIa but also directly interacts with macromolecular substrate. In particular, Lys residues 165 and 166, located in a membrane proximal position in the carboxyl-terminal module of TF, contribute to protein-protein interactions with the coagulation factor X (X) Gla domain (15, 16). The Gla domain of substrate docks into a larger collision surface constituted by the VIIa Gla domain (17, 18) in complex with the carboxyl-terminal module of TF (19).

Monoclonal antibodies to TF (20) and VIIa (21) have provided further evidence for the location of exosites for macromolecular substrate recognition. Notably, these monoclonal antibodies acted as competitive inhibitors of macromolecular substrate binding, as evidenced by a pronounced effect on the K_m for X activation (21, 22). These data are consistent with the hypothesis that proper presentation and activation of natural substrate are critically dependent on binding of the macromolecular substrate with exosite regions involving both cofactor and enzyme. Active site-inhibited thrombin has been shown to act as an efficient competitive inhibitor for macromolecular substrate activation by the prothrombinase complex, leading to the proposal that exosite docking is the major determinant for macromolecular substrate affinity (23). Moreover, a proteolytic fragment of thrombin that corresponds to the carboxyl-terminal half of the protease domain contains the necessary structural elements for macromolecular substrate docking with the prothrombinase complex (24). Because this fragment contains most of the loop segments known as the "activation domain," which are highly flexible prior to proteolytic zymogen activation or inhibitor modification (25, 26), it remains to be established to what extent the active site blocked thrombin and derived fragments faithfully mimic the cofactor/enzyme docking mode of the zymogen-substrate protease domain.

In order to investigate the role of scissile bond docking within the structural context of the intact zymogen, we mutated the P1 Arg residue in macromolecular substrate X. This mutation of the primary specificity determinant in substrate, as well as of recognition determinants in the catalytic cleft of VIIa that impair the interactions of the scissile bond with the active site of the enzyme, failed to reduce affinity for X, demonstrating that exosite docking is the only critical factor that governs macromolecular substrate affinity for TF·VIIa. By providing direct and independent experimental evidence, these data thus allow generalization of the hypothesis that specificity of the highly homologous, cofactor-dependent upstream coagulation serine proteases is achieved by macromolecular substrate recognition determinants of exosites, rather than sequence specificity of the catalytic cleft.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Proteins-- Full-length recombinant human TF was produced from insect cells and reconstituted into 30% phosphatidylserine/70% phosphatidylcholine (TF/PCPS), or 100% phosphatidylcholine (TF/PC), as described (27). The soluble extracellular domain of TF, TF_1-218, was expressed in Escherichia coli and purified and refolded from inclusion bodies, as described (28). X was purified from plasma, followed by immunoaffinity chromatography on immobilized monoclonal antibody F21-4.2 to reduce contamination by VII (1). Monoclonal antibody F3-3.2A to VII/VIIa was characterized previously (21). Recombinant wild-type and mutant VII were expressed in Chinese hamster ovary cells and purified by sequential monoclonal antibody and ion exchange chromatography, as described (27). Because of slow zymogen to enzyme conversion VII_Ala-40 and VII_Ala-99 activation was accelerated by addition of factor IXa, as described (1). Mutant and wild-type VIIa were active site blocked with D-Phe-L-Phe-Arg chloromethylketone (Calbiochem) to yield >98% modification, as determined by amidolytic assay (29). Gla content of the mutants, determined by amino acid analysis of alkaline hydrolysates performed at Commonwealth Biotechnologies (Richmond, VA), showed a full complement of Gla residues indistinguishable from wild-type recombinant VIIa.

Recombinant X production has previously been described in detail (18). All mutations were introduced into a cDNA clone with a propeptide mutation at position Thr-2 to Arg to facilitate cellular processing (30) and mutations of Asn-181 and Asn-191 (residue numbering based on Ref. 31) to Ala and Asp, respectively, to eliminate heterogeneity from glycosylation of the activation peptide. We had previously characterized this recombinant protein that is efficiently activated by TF·VIIa (18). To generate an inactive substrate mimic suitable for competition studies with wild-type X, the catalytic triad Ser-195 was mutated to Ala. When activated by TF·VIIa, this mutant, X_{Arg-15,Ala-195}, lacked amidolytic activity. The scissile bond P1 (2) residue Arg was additionally mutated to Gln in another mutant, X_{Gln-15,Ala-195}, to generate a macromolecular substrate mimic that fails to properly dock into the S1 specificity pocket. Both mutants were stably expressed in dihydrofolate reductase-deficient Chinese hamster ovary cells, and each protein was purified from serum-free culture supernatants with immobilized anti-X monoclonal antibody F21-4.2C. Protein with partial degradation of the Gla domain was separated in a barium citrate precipitation step from fully -carboxylated protein that has a properly folded Gla domain (18). The eluates from the barium citrate precipitate were dialyzed extensively against Tris-buffered saline for storage at 70 °C. A final pass over a benzamidine-Sepharose column equilibrated with Tris-buffered saline was used to eliminate trace contaminants of activated X that may have been generated during production or purification of the recombinant protein. The termini of light and heavy chains of the mutants were confirmed by amino-terminal sequencing, which showed <4% yield for Glu-7 and Glu-8, consistent with complete -carboxylation of these Gla positions.

Functional Assays-- K_m and k_cat for X hydrolysis by TF·VIIa were determined with a fixed concentration (200 pM) of TF/PC or TF/PCPS and excess wild-type or mutant VIIa (1 nM) in HEPES-buffered saline (10 mM HEPES, 150 mM NaCl, pH 7.4), 5 mM CaCl₂, 0.2% bovine serum albumin. After a brief preincubation (5 min) of TF with VIIa to allow for complex formation, X (0.2 nM to 10 µM) was added, and activation was determined in samples quenched with 100 mM EDTA, using the chromogenic substrate Spectrozyme FXa. Initial rate data were fitted to the Michaelis-Menten equation.

The interaction of inactive X mutants with TF·VIIa was analyzed in a competitive inhibition assay with wild-type, plasma-derived X. After forming the TF·VIIa complex on PCPS vesicles under the conditions described above, wild-type X and X_{Arg-15,Ala-195} or X_{Gln-15,Ala-195} were added simultaneously, followed by quenching with EDTA and determination of the generation of active Xa with Spectrozyme FXa. Initial rate data were obtained in three independent experiments for wild-type X concentrations of 0.2-10 µM at each of the inhibitor concentrations used. The means of the initial velocity data were fitted to the Michaelis-Menten equation to determine the apparent K_m and k_cat for X activation. Both mutants showed competitive inhibition of X activation. K_i values were determined from the replot of the K_m values versus the competitor concentration (0-400 nM) for each of the mutants.

Amidolytic function of wild-type or mutant VIIa (5 nM) was measured in the presence of increasing concentrations of soluble TF_1-218 (0.5-100 nM) with 0.5 mM chromogenic substrate Chromozym t-PA (Roche Molecular Biochemicals) in Tris-buffered saline, 5 mM CaCl₂, 0.2% bovine serum albumin, pH 8.0. Kinetic parameters for chromogenic substrate hydrolysis were determined at a fixed enzyme (30 nM) and cofactor TF_1-218 (120 nM) concentration with varying concentrations of substrate (1.5 mM to 10 µM) under the same buffer conditions.

Surface Plasmon Resonance Analysis-- Binding constants were determined on BIAcore 2000 instruments. Monoclonal antibodies to VII (F3-3.2A) and to TF (TF9-10H10) were directly immobilized by coupling through free amino groups to a carboxylated dextran matrix, activated with a mixture of N-hydroxysuccinimide and N-ethyl-N'-[3-(diethylamino)propyl]carbodiimide, as described previously (29). Association kinetics for binding to F3-3.2A were measured by injecting various concentrations (13 nM to 4 µM) of mutant or wild-type VIIa with or without active site modification onto the antibody-coated sensorchip. Determination of binding kinetics of wild-type and mutant VIIa to TF utilized capturing of full-length TF to the noninhibitory antibody TF9-10H10 (29). Experiments were performed in HEPES-buffered saline, 5 mM CaCl₂, 0.005% surfactant P20, and 3 mM Chaps at a 30 µl/min flow rate. Association rate constants (k_s) were calculated from at least five concentrations of VIIa. The k_on was determined from the concentration dependence of k_s, and the k_off was determined from analysis of the response curve upon return to buffer flow.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Determination of Macromolecular Substrate Affinity for TF·VIIa by Competitive Assay-- To analyze macromolecular substrate docking with TF·VIIa, we mutated the catalytic triad Ser to Ala to generate a catalytically inactive X molecule. In the first mutant, X_{Arg-15,Ala-195}, the scissile bond P1 residue Arg was unchanged. As expected, X_{Arg-15,Ala-195} had no measurable catalytic activity after zymogen activation and thus did not interfere with functional amidolytic assays. X_{Arg-15,Ala-195} inhibited the activation of wild-type macromolecular substrate X by phospholipid-associated TF·VIIa. The display of kinetic analysis by Lineweaver-Burk plots demonstrate that X_{Arg-15,Ala-195} has no effect on the v_max but increases the apparent K_m in a dose-dependent manner, consistent with simple competitive inhibition (Fig. 1). The mutant inhibited wild-type X with a K_i of 34 ± 3 nM, which is comparable to the K_m for wild-type X activation under these experimental conditions. Hydrolysis of the peptidyl substrate Chromozym t-PA (0.5 mM) by 30 nM VIIa in complex with 120 nM TF_1-218 was measured in the presence or absence of 2.5 µM X_{Arg-15,Ala-195}. The rate of hydrolysis in the presence (81 ± 5 relative absorbance/min) or absence (83 ± 3 relative absorbance/min) of the inactive X mutant were indistinguishable, supporting the notion that X_{Arg-15,Ala-195} competes with docking of macromolecular substrate, rather than inhibits scissile bond cleavage in the active site cleft.

View larger version (15K): [in this window] [in a new window]   Fig. 1.   Lineweaver-Burk plots of wild-type X activation in the presence of increasing concentrations of inactive X mutants. The top panel shows competition by XArg-15,Ala-195 at 0 (), 50 (), 100 (), 200 (), and 400 () nM; the bottom panel shows competition by XGln-15,Ala-195 over the same concentration range. Activation of the indicated concentrations of wild-type, plasma-derived X with 1 nM VIIa in the presence of 200 pM TF/PCPS was analyzed at 37 °C.

Mutation of the P1 Residue in X Does Not Influence Affinity for Docking with TF·VIIa-- To analyze the importance of the P1 residue for macromolecular substrate affinity, the P1 residue Arg in X was replaced by Gln. Fig. 2 shows the time-dependent activation of catalytically inactive X mutants with either Arg or Gln as the P1 residues. Whereas the activation of X_{Arg-15,Ala-195} approached completion after 15 min, no activation was detectable after 1 h in the case of X_{Gln-15,Ala-195}. This demonstrates that mutation of P1 to Gln prevents scissile bond cleavage, which is likely attributable to a failure of the Gln residue to properly bind to the S1 specificity pocket. As found with X_{Arg-15,Ala-195}, the P1 Gln mutant X_{Gln-15,Ala-195} (2.5 µM) failed to inhibit amidolytic function of VIIa (30 nM) in complex with 120 nM TF_1-218 (83 ± 3 relative absorbance/min without versus 82 ± 3 relative absorbance/min with X_{Gln-15,Ala-195}), arguing that this mutant P1 residue does not occupy the S1 subsite without subsequent scissile bond cleavage. X_{Gln-15,Ala-195} was as potent a competitor as X_{Arg-15,Ala-195} for X docking to TF·VIIa. The Lineweaver-Burk plots show competitive inhibition by X_{Gln-15,Ala-195} (Fig. 1), and the calculated K_i of 40 ± 4 nM was indistinguishable from X_{Arg-15,Ala-195}. These data demonstrate that the P1 residue in X makes no measurable contribution to the affinity of macromolecular substrate binding to TF·VIIa.

View larger version (42K): [in this window] [in a new window]   Fig. 2.   Activation of XArg-15,Ala-195 and XGln-15,Ala-195. 10 µM XArg-15,Ala-195 or XGln-15,Ala-195 was incubated with 50 nM VIIa/50 nM TF/PCPS for the indicated times, followed by separation by SDS-polyacrylamide gel electrophoresis under reducing conditions and Coomassie Blue staining.

Mutation of Catalytic Cleft Residues in VIIa-- This conclusion would predict that mutations in the catalytic cleft of VIIa, to which the activation peptide region of macromolecular substrate binds, should not affect the affinity of TF·VIIa for X. To test this hypothesis, two residue positions in the catalytic cleft were selected for replacement with Ala. On the S subsite, Thr-99 makes contacts with the P2 residue, as shown in the crystal structure of the Phe-Phe-Arg-inhibited TF·VIIa complex (19). On the S' subsite, residue Gln-40 was mutated. Although the precise docking of the P' residues of coagulation serine protease substrates is not known, a recent crystal structure of TF·VIIa in complex with the Kunitz-type inhibitor 5L15 shows contacts of Leu-39, adjacent to Gln-40, with the P2' position of the inhibitor (32), indicating perturbation of the proximity of the S2' subsite by the Gln-40 mutation. The mutants were purified to homogeneity and characterized by surface plasmon resonance analysis for binding interactions to validate the overall proper folding of the proteins.

The mutations had little effect on VIIa binding to TF (Table I). In addition, active site modification with the covalent inhibitor Phe-Phe-Arg chloromethyl ketone increased affinity for each of the mutants, as previously found for wild-type VIIa (29). This demonstrates that these mutations in the catalytic cleft do not diminish cofactor binding (TF) or disrupt allosteric changes that link the active site to the cofactor binding site. Using a previously characterized, conformation sensitive monoclonal antibody (F3-3.2A) to the VIIa protease domain exosite that participates in X docking (21), we further analyzed conformational changes in this exosite region of VIIa. VIIa_Ala-40 and VIIa_Ala-99 bound to F3-3.2A with the same affinity as wild-type VIIa and displayed a loss of affinity upon active site modification in accordance with that of wild-type (Table I). These data argue that the mutational effect of these two replacements is confined to the active site cleft and does not influence the overall conformation or active site occupancy-related allosteric changes in the VIIa protease domain.

The unaltered affinity for TF is further demonstrated by dose titration with soluble TF_1-218 in the amidolytic assay shown in Fig. 3. Whereas VIIa_Ala-40 hydrolyzed the chromogenic substrate Chromozym t-PA with similar efficiency as wild-type VIIa, a dramatic reduction in amidolytic activity for VIIa_Ala-99 was observed. Kinetic parameters for cleavage of this substrate were determined at a fixed enzyme concentration, demonstrating that the loss of catalytic function of VIIa_Ala-99 resulted predominantly from a significant decrease in the affinity for the p-nitroanilide substrate (Table II). These results are expected from a modification of the S2 subsite, because the activation of small substrates is highly dependent on the docking to the S1-3 subsite, with little contribution of binding of the p-nitroanilide group to the S' subsite.

View larger version (21K): [in this window] [in a new window]   Fig. 3.   Amidolytic activity of site-directed mutants of VIIa. The hydrolysis of the chromogenic substrate Chromozym t-PA (0.5. mM) by 5 nM mutant VIIaAla-40 (), mutant VIIaAla-99 (), or wild-type VIIa () in the presence of increasing concentrations of soluble TF1-218 was analyzed at ambient temperature.

Effect of Mutations in the Catalytic Cleft on Macromolecular Substrate Binding-- The activation of macromolecular substrate X by the two VIIa mutants was analyzed on both charged PCPS and neutral PC vesicles. Mutation of Gln-40 at the S' subsite did not affect the K_m, but reduced the k_cat 2-fold independent of the lipid composition of the vesicles (Table II). These data indicate that S' subsite docking of the scissile bond makes no contribution to the affinity of macromolecular docking with TF·VIIa, although it is critical for the efficiency of hydrolysis of the peptide bond. This conclusion is further supported by the kinetic parameters for VIIa_Ala-99 that displayed a greatly reduced affinity for small substrate, which solely bind to the catalytic cleft of VIIa. The k_cat for X activation was reduced 6-fold upon Thr-99 mutation, but the K_m was unchanged. Mutations of catalytic cleft residues in VIIa thus do not influence macromolecular substrate affinity, although scissile bond-mimicking chromogenic substrates display an increased K_m for these mutants. These data are consistent with the conclusions drawn from the analysis of mutations of the X P1 position that also did not influence the affinity for TF·VIIa.

Based on these results, one would further predict that the affinities of the inactive X mutants for TF·VIIa are not influenced by the mutations in the catalytic cleft of VIIa. X_{Arg-15,Ala-195} and X_{Gln-15,Ala-195} were used as competitive inhibitors for wild-type X activation by both VIIa mutants in the presence of TF. The inactive X mutants exhibited pure competitive inhibition with each of the VIIa mutants, as shown for wild-type VIIa in Fig. 1. The K_i values calculated for these experiments (Table III) demonstrate that X_{Arg-15,Ala-195} bound to each of the mutants with the same affinity as to wild-type VIIa in complex with TF. Furthermore, there was no effect of mutation of the P1 Arg residue to Gln on the affinity for the VIIa mutants. These data thus emphasize that neither docking of the scissile bond P1 residue nor interaction at the S or the S' subsites contributes to X affinity for TF·VIIa, indicating that substrate recognition at exosite regions of cofactor and enzyme is the key determinant for macromolecular substrate binding and specificity.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

In this study, site-specific mutagenesis was employed to determine whether binding of the activation peptide region of X to the active site cleft of TF·VIIa plays a significant role in macromolecular substrate affinity. In two independent experimental approaches, we found that scissile bond docking does not measurably contribute to macromolecular substrate affinity of the TF·VIIa complex. First, we generated catalytically inactive X mutants that can be used in a competitive assay with wild-type X. X_{Arg-15,Ala-195} showed pure competitive inhibition of wild-type X activation by TF·VIIa with a K_i that was indistinguishable from the K_m of wild-type X activation. Thus, this mutant truly recapitulates the docking of the macromolecular substrate. Mutation of the P1 Arg residue in X_{Gln-15,Ala-195} produced a mutant that was resistant to activation by TF·VIIa and that did not inhibit amidolytic function of the complex, indicating that the mutated P1 residue fails to bind productively to the S1 subsite of the enzyme. X_{Gln-15,Ala-195} was equally potent as X_{Arg-15,Ala-195} as a competitive inhibitor of X activation by TF·VIIa, demonstrating that P1 docking to the S1 subsite makes no appreciable contributions to macromolecular substrate binding with TF·VIIa in a physiologically assembled ternary complex.

Second, mutations of residues in the S and S' subsites of the catalytic cleft did not increase the K_m for macromolecular substrate activation. The mutation of the S2 subsite residue significantly reduced the affinity for a small chromogenic p-nitroanilide substrate without major effects on the k_cat, demonstrating that the catalytic cleft structure is sufficiently perturbed to interfere with normal docking of activation peptide-mimicking pseudosubstrates. However, the mutations in the catalytic cleft of VIIa only reduced the k_cat of macromolecular substrate X activation, suggesting that transition state formation and the subsequent acylation/deacylation steps are rate-limiting in protein substrate activation. These data are consistent with a two step process in which macromolecular substrate docking precedes scissile bond interactions with the catalytic cleft, as suggested for prothrombin activation (23, 24). Other mutations in or near the catalytic cleft of VIIa have previously been shown to have a similar effect on X activation. In particular, Ala replacements for Lys-192 (33), located just above the S1 pocket, and the immediately adjacent Arg-148 in the autolysis loop (27) both reduced the k_cat for X activation without influencing the K_m. Because Arg-148 is localized in one of the nonconserved loop regions of the serine protease domain that are considered important for substrate specificity (34), the selective effect of the Arg-148 mutation on the k_cat may indicate that even these specificity determinants more distant from the scissile bond, but in proximity to the catalytic cleft, are not involved in the initial docking of macromolecular substrate.

Indirect support for a minor importance of scissile bond docking for macromolecular substrate affinity is further provided by the kinetic mechanism of inhibitors of the TF·VIIa complex. Both the nematode inhibitor NAPc2 (35) and the natural inhibitor of TF pathway inhibitor (36), are dependent on the product Xa for efficient inhibition of the TF·VIIa complex. Kinetic analysis of the mechanism of inhibition in the latter case clearly demonstrated that the preferred target for inhibition by TFPI is the ternary complex of TF·VIIa·Xa (37), emphasizing that extended macromolecular substrate interactions that may be partially preserved in the product are of sufficient affinity to transiently stabilize the ternary complex. The Gla domain of substrate X is critical for binding to the collision structure of TF and the VIIa Gla domain (15, 16, 18), and mutations in TF that reduce substrate binding also influence the inhibition by the TFPI·Xa complex (38). Furthermore, fusion of the light chain of Xa amino-terminal to TFPI generates an inhibitor chimera with greatly enhanced affinity for TF·VIIa as compared with TFPI alone (39). It thus appears that the light chains of the upstream coagulation proteases evolved to direct the specificity of the interactions between substrates and the cell surface-associated enzyme-cofactor complexes.

The kinetic mechanism of activation of X by TF·VIIa may serve to illustrate a fundamental difference between serine proteases that initiate and propagate enzyme cascades as opposed to effector proteases. Whereas the former typically function in a membrane-localized environment, the latter frequently require diffusion to specific targets and catalyze fluid phase reactions, such as the conversion of fibrinogen to fibrin by thrombin. High affinity for product would significantly impair the catalytic rate of effector proteases. To reduce product inhibition, the cleavage bond vicinity of substrate may have been preferentially evolved as the major determinant for substrate affinity for effector proteases. In contrast, the rate of cleavage may be of secondary importance relative to the requirement for a high degree of specificity in recognition of homologous enzymes when activating an amplifying, consecutive cascade. The versatility of extended recognition surfaces to generate highly specific reaction partners from similar protein modules may have been the driving force in the evolution of enzyme cascades, such as the coagulation system. The high degree of biological fidelity that was achieved by creating specificity through extended recognition surfaces of enzyme-cofactor complexes may have resulted in a lack of evolutionary pressure to imprint substrate affinity and specificity into recognition determinants of the catalytic cleft.

	ACKNOWLEDGEMENTS

We thank Jennifer Royce and David Revak for excellent technical assistance in recombinant protein production and purification.

	FOOTNOTES

^* Supported by National Institutes of Health Grants R01 HL48752 and P01 HL16411. Performed during the tenure of an Established Investigator Award from the American Heart Association (to W. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Depts. of Immunology and Vascular Biology, IMM-17, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-784-2748; Fax: 858-784-8480; E-mail: ruf@scripps.edu.

	ABBREVIATIONS

The abbreviations used are: VIIa, coagulation factor VIIa; TF, tissue factor; X, coagulation factor X; PC, phosphatidylcholine; PCPS, phosphatidylcholine/phosphatidylserine; Chaps, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; TFPI, TF pathway inhibitor.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				H. H. Versteeg and W. Ruf Tissue Factor Coagulant Function Is Enhanced by Protein-disulfide Isomerase Independent of Oxidoreductase Activity J. Biol. Chem., August 31, 2007; 282(35): 25416 - 25424. [Abstract] [Full Text] [PDF]

				T. Ogawa, I. M. Verhamme, M.-F. Sun, P. E. Bock, and D. Gailani Exosite-mediated Substrate Recognition of Factor IX by Factor XIa: THE FACTOR XIa HEAVY CHAIN IS REQUIRED FOR INITIAL RECOGNITION OF FACTOR IX J. Biol. Chem., June 24, 2005; 280(25): 23523 - 23530. [Abstract] [Full Text] [PDF]

				D. S. Boskovic, T. Troxler, and S. Krishnaswamy Active Site-independent Recognition of Substrates and Product by Bovine Prothrombinase: A FLUORESCENCE RESONANCE ENERGY TRANSFER STUDY J. Biol. Chem., May 14, 2004; 279(20): 20786 - 20793. [Abstract] [Full Text] [PDF]

				E. P. Bianchini, R. N. Pike, and B. F. Le Bonniec The Elusive Role of the Potential Factor X Cation-binding Exosite-1 in Substrate and Inhibitor Interactions J. Biol. Chem., January 30, 2004; 279(5): 3671 - 3679. [Abstract] [Full Text] [PDF]

				H. R. Maun, C. Eigenbrot, and R. A. Lazarus Engineering Exosite Peptides for Complete Inhibition of Factor VIIa Using a Protease Switch with Substrate Phage J. Biol. Chem., June 6, 2003; 278(24): 21823 - 21830. [Abstract] [Full Text] [PDF]

				M. F. Hockin, K. C. Jones, S. J. Everse, and K. G. Mann A Model for the Stoichiometric Regulation of Blood Coagulation J. Biol. Chem., May 17, 2002; 277(21): 18322 - 18333. [Abstract] [Full Text] [PDF]

				M. Riewald and W. Ruf Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor PNAS, July 3, 2001; 98(14): 7742 - 7747. [Abstract] [Full Text] [PDF]

				S. IDELL, A. P. MAZAR, P. BITTERMAN, S. MOHLA, and A. L. HARABIN Fibrin Turnover in Lung Inflammation and Neoplasia Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 578 - 584. [Full Text]

				R. J. Baugh, C. D. Dickinson, W. Ruf, and S. Krishnaswamy Exosite Interactions Determine the Affinity of Factor X for the Extrinsic Xase Complex J. Biol. Chem., September 8, 2000; 275(37): 28826 - 28833. [Abstract] [Full Text] [PDF]

				P. W. Bergum, A. Cruikshank, S. L. Maki, C. R. Kelly, W. Ruf, and G. P. Vlasuk Role of Zymogen and Activated Factor X as Scaffolds for the Inhibition of the Blood Coagulation Factor VIIa-Tissue Factor Complex by Recombinant Nematode Anticoagulant Protein c2 J. Biol. Chem., March 23, 2001; 276(13): 10063 - 10071. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shobe, J. Articles by Ruf, W. Search for Related Content PubMed PubMed Citation Articles by Shobe, J. Articles by Ruf, W.